CD70 and neoplasm: In addition, chimeric antigen receptor (CAR)-T cell therapy in which T cells are genetically engineered to recognize tumor antigens (melanoma-associated antigen-A3, mesenchymal epithelial transition, CD70, GD2, etc.)has also entered clinical trials in melanoma immunotherapy 49, 50.